Roche launches innovative dual antigen and antibody diagnostic test supporting the fight to eliminate the hepatitis C virus

Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.TheElecsys HCVDuo immunoassay enables significantly earlier diagnosis of active HCV infection, making it possible to get patients appropriate care sooner to stop both the disease progression and transmission.Basel, 18 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Elecsys ® HCV Duo immunoassay in countries that accept the CE Mark. Elecsys HCV Duo is the first available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status from a single human plasma or serum sample. This means that the test c an be used to detect the early stage of infection, as well as when the patient is recovering from the virus, or showing signs of a chronic infection that may lead to other diseases, such as liver cancer.By utilising the dual detection of HCV core antigen and antibodies to HCV, the Elecsys HCV Duo assay enables significantly earlier diagnosis of active hepatitis C virus infection compared to using antibody-only assays, as core antigen appears early in the course of infection and is a marker of ongoing viral replication. This can lead to earlier intervention for patients, reduction in the number of clinic visits needed to take additional test samples and can alleviate some of the testing burden on healt...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news